Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2018-07
-
br New AMPK activators Fenofibrate is
2024-04-18

New AMPK activators Fenofibrate is a drug of the fibrate class used for the treatment of dyslipidemia [53] but is also an agent that could alleviate DN-induced alterations through AMPK activation (Fig. 2). Streptozotocin-induced diabetic rats treated with fenofibrate improved in not only renal fu
-
Some alterations in the integrity of cell membranes caused
2024-04-18

Some alterations in the integrity of cell membranes caused by toxic agents can be determined by measuring certain enzymes released by damaged cells [8]. The cholinesterases, for example, catalyze the hydrolysis of CD 3254 (ACh) in choline and acetic acid. Theses enzymes are divided into two types:
-
PL for actin in vitro showed that
2024-04-18

PL for beta-lactamase in vitro showed that its profiles, including particular peak and intensity, could determine the length and thickness of an actin filament. Furthermore, we investigated if the PL intensity peak at approximately 340 nm can also be originated from another cytoskeleton filament, s
-
The AChR is composed of five homologous membrane spanning
2024-04-18

The AChR is composed of five homologous, membrane-spanning subunits. AChRs containing two α, one β, one δ and one γ subunit (AChRγ) predominate during embryonic development and mice lacking AChRγ die at birth (Takahashi et al., 2002). After birth, the AChRγs are replaced during the first 2 postnatal
-
Two patients developed diffuse mesangio
2024-04-18

Two patients developed diffuse mesangio-proliferative glomerulonephritis (DMPG) postoperatively, presenting as nephrotic syndrome and benign haematuria, respectively. DMPG has been reported in an adult patient with thymomatous MG following thymectomy [35], and various types of glomerulonephritis hav
-
In vitro studies with soman inhibited non
2024-04-18

In vitro studies with soman-inhibited, non-aged AChE revealed a species dependent reactivating potency of HI-6 and MMB-4. With guinea pig AChE second order reactivation rate constants of 0.051 and 0.038mM−1min−1 were determined for HI-6 and MMB-4, respectively (Luo et al., 2007). Corresponding value
-
Normally the activity of the lyase increases with
2024-04-18

Normally, the activity of the 17,20-lyase increases with the onset of adrenarche [7], [8], [15]. Adrenarche has previously been perceived as a relatively sudden event, occurring physiologically between 6 and 8years of age. However, results from our laboratory clearly indicated that adrenarche is a c
-
MPC 6827 hydrochloride br Materials and methods br Results b
2024-04-18

Materials and methods Results Discussion We have developed a high-throughput functional genomic screen that allows the identification of genes that confer drug resistance. Several factors have been identified which must be taken into account to develop a reliable screen. In particular, cons
-
In many cells AR mediated activation of PLC has been
2024-04-18

In many Glyoxalase I inhibitor mg α1-AR mediated activation of PLC has been shown to be the downstream process for NA-induced signalling. The activated PLC initiates subsequent signalling by breakdown of PIP2 to IP3 and DAG (Fisher and Agranoff, 1987) and the process continues. To confirm if such me
-
Phagosomes acquire some hydrolases early
2024-04-18

Phagosomes acquire some hydrolases early during their journey from the cell surface to lysosomes. An example for such hydrolase is cathepsin H which is most concentrated in the early phagosome at a pH of approximately 6.3 (Claus et al., 1998), the pH optimum of enzyme activity (Schwartz and Barrett,
-
In the present study we showed that LOX metabolites
2024-04-17

In the present study, we showed that 15-LOX metabolites, which are the precursors of anti-inflammatory and pro-resolving lipid mediators, were decreased in the unaffected skin area of the OS model rats by comprehensive lipidomics analyses. Furthermore, subsequent microarray analyses demonstrated tha
-
There are increasing repeated reports of amphotericin B resi
2024-04-17

There are increasing repeated reports of amphotericin B-resistance in pathogenic fungi including Candida spp. [35], [36]. Nolte et al. characterized some fluconazole and amphotericin B-resistant Candida albicans isolates from leukemia patients [37]. Fan-Havard et al. (1991) have shown multi-antifung
-
br Introduction Heart failure HF is
2024-04-17

Introduction Heart failure (HF) is a chronically progressive disease and one of the most important causes of morbidity and mortality worldwide despite recent improvements in its treatment [1], [2], [3]. The mortality and morbidity benefits of angiotensin converting enzyme inhibitor (ACEI) are wel
-
AMD3100 In summary the CV and renal benefits of
2024-04-17

In summary, the CV and renal benefits of sacubitril/valsartan in HF patients are attributed to the increased levels of peptides that are degraded by neprilysin and the simultaneous inhibition of the effects of AT1 receptor by valsartan (Fig. 1). Physical and chemical properties Sacubitril/Valsar
-
The major phase trial NCT enrolled participants with mild
2024-04-17

The major phase 2 trial (NCT01343966) enrolled 431 participants with mild to moderate AD who received either low-dose SC crenezumab 300 mg or placebo biweekly (n = 184) or high-dose intravenous crenezumab 15 mg/kg or placebo every 4 weeks (n = 247) for 68 weeks 38, 40. No significant treatment benef
15007 records 184/1001 page Previous Next First page 上5页 181182183184185 下5页 Last page